Speakers

Expand/Collapse

Adam Wilkinson
Pre-Clinical Development
Microbiotica

Track B - Afternoon - Day One

11:50 am | A Clinically-Defined Multifunctional Bacterial Consortium for the Treatment of Ulcerative Colitis

Alex Stevenson
CSO
4D Pharma PLC

Day Two

Thursday, 27th January 2022

3:55 pm | Taking the Microbiome Beyond the gut – Realizing the Full Potential of Microbiome Therapies Through Targeted Systemic Effects

Alice Eggleston
Physician Assistant
Atlantia Food Clinical Trials

Anders Damholt
Head of Clinical Development
Chr. Hansen

Day Two

Thursday, 27th January 2022

9:55 am | Discover how Biomarkers are Developing & Validating Therapeutic Targets

Audrey Maudhuit
European Process Engineer
Fluid Air

Day 2 - Track A Evening

2:45 pm | Optimized Continuous Drying for Microbiome Applications

Barbara McGovern, M. D.
VP Medical Affairs
Seres Therapeutics

Day 2 - Track B Evening

2:55 pm | ECOSPOR III data

Barry Skillington
Chief Commercial Officer
Atlantia Clinical Trials

Track B - Evening - Day One

2:20 pm | Considerations When Selecting a Clinical Partner

Bart Roucourt
Business Development Director
ProDigest

Day 2 - Track A Afternoon

12:45 pm | Technology platforms for accelerating R&D of LBPs for the gastrointestinal tract

Benjamin Hadida
CEO and Co-Founder
Exeliom Bio

Track A - Evening - Day One

1:20 pm | Developing Faecalibacterium prausnitzii as a Novel Live Biotherapy for Inflammatory Bowel Diseases

Bernard Walther
Director, Drug Safety and Pharmacokinetics
Servier

Day Two

Thursday, 27th January 2022

8:25 am | Medicen Initiative

Celine Druart
Pharmabiotic Research Institute
Microbiome Project Manager

Day Two

Thursday, 27th January 2022

4:55 pm | Equip and De-Risk Your Microbiome Drug Development for the European Market - Regulatory Science and a ‘Development-by- Design’ Approach

Charles Bundinof
Strain Discovery and Microbiome Science Lead
IFF

Track A - Evening - Day One

2:20 pm | Probiotic Consortia Improve Anti-viral Immunity

Chris Ford
Senior Director, Computational Microbiome Science
Seres Therapeutics

Christophe Clarite
CMO
4D Pharma PLC

Day 2 - Track A Afternoon

11:15 am | Effectively Scaling Up Microbial Therapeutic Manufacturing

12:15 pm | Delve Into Manufacturing and Controls of LBPs: Meeting GMP and Regulator guidelines

David Ege
EVP Bioprocess & Manufacturing, Chief Technology Officer
Seres Therapeutics

Day 2 - Track A Afternoon

11:15 am | Effectively Scaling Up Microbial Therapeutic Manufacturing

Declan Jones
VP, Head of External Innovation & Scientific Licensing
Ferring Pharmaceuticals

Day One

Wednesday, 26th January 2022

8:05 am | European Microbiome Leaders Panel Discussion

Denise Kelly
Investment Advisor
Seventure

Day One

Wednesday, 26th January 2022

8:05 am | European Microbiome Leaders Panel Discussion

Day Two

Thursday, 27th January 2022

8:55 am | Building Investor Confidence in Microbiome Drug Development; how to Promote And Restore Confidence

Dr. Adam Rosenthal
Health & Biosciences, Research & Development
IFF

PRE-CONFERENCE WORKSHOP DAY | TUESDAY 25TH JANUARY 2022 Workshop C - 'Identifying Drug Targets With Bacterial Single Cell Tools'

Dr. Nga Le
Process Engineer
Fluid Air

Duncan Peyton
CEO
4D Pharma PLC

Day One

Wednesday, 26th January 2022

8:05 am | European Microbiome Leaders Panel Discussion

Edward Green
CEO
CHAIN Biotechnology LTD

Track B - Afternoon - Day One

11:20 am | Oral Drug Delivery to the Lower GI

Emilie Plantamura
Medical and Scientific Expert – Oncohematology
MaaT Pharma

Day 2 - Track B Evening

1:45 pm | MaaT013 - A Dysbiosis Correcting Live Biotherapeutic for the Treatment of Acute Graft-vs-host-Disease

Fabio Grassi
Founder
MV BioTherapeutics

Track A - Afternoon - Day One

10:20 am | Microbiota Adaptation via Secretory IgA to Correct Dysbiosis

Felix Faupel
Chief Commercial Officer
Bacthera

Day One

Wednesday, 26th January 2022

9:20 am | De-risk your CMC and maximize value for your LBP production. We are your strategic collaboration and CDMO partner for the entire LBP journey

Gabriel Leventhal
Head of R&D
PharmaBiome

Track A - Evening - Day One

2:50 pm | Next Steps for Omics: Niche Mapping the Microbiome to Gain a Functional Understanding of Dysbiosis

Georges Rawadi
CEO
YSOPIA Bio

Grégoire Chevalier
Scientific Affairs Manager
Enterome

Day 2 - Track B Afternoon

11:45 am | Harnessing the Microbiome for Drug Discovery: the Example of a Microbiome-Derived Therapeutic for Ulcerative Colitis

Hervé Affagard
CEO
MaaT Pharma

Day One

Wednesday, 26th January 2022

8:05 am | European Microbiome Leaders Panel Discussion

Igor Stzepourginski
Head of Preclinical Operations
Eligo Bioscience

Day 2 - Track A Evening

1:45 pm | A Novel Therapeutic Approach for the Elimination of Harmful Bacteria From the Microbiome

Jack Gallagher
CEO
Clarity Pharma

Track B - Evening - Day One

2:50 pm | Optimizing the Exploding Power of Microbiome Predictive Analytics Will Require Applying the Laws of Behaviour and Risk Perception to Influence a Patient’s Downstream Health Decisions

Jeff Heiser
Head of Quality Control/Analytical Development
Arranta Bio

Day One

Wednesday, 26th January 2022

5:00 pm | Investing in the Analytical Methods and Facilities for the Future of Live Biotherapeutic Products

Jenny Bailey
CEO
Ferryx

Day Two

Thursday, 27th January 2022

4:25 pm | Inflammation, Iron And the gut Microbiome; Challenges for Mitigating the Effects of Inflammatory Bowel Disease Using LBPs

John Hambor
Director, Research Beyond Borders
Boehringer Ingleheim

Karine Roget
CSO
Nexbiome

Day 2 - Track B Afternoon

12:15 pm | BGY-1601, Vaginal tablet: a “Universal” First-Line Monotherapy of Acute Vaginitis Symptoms

Kristin Wannerberger
Director R&D Alliance Management
Ferring Pharmaceuticals

Day One

Wednesday, 26th January 2022

4:30 pm | Ferring & the Microbiome

Luc Sterkman
CEO
Caelus Health

Day 2 - Track B Afternoon

11:15 am | A Deep Dive Into the Potential of Microbiome Therapeutics in Cardiometabolic And Related Disorders

Lutz Kraus
Head of Data-Mining and Artifical Intelligence
Microba

Day Two

Thursday, 27th January 2022

10:25 am | Data Directed Discovery of Microbiome Derived Therapeutics

Manoj Dadlani
CEO
CosmosID

Matthew Robinson
VP Translational Biology
Microbiotica

Day Two

Thursday, 27th January 2022

9:25 am | Using Precision Microbiome Profiling to Develop a Biomarker for Immune Checkpoint Inhibitor Response and a Potent Therapeutic Consortium

Mike Ramonas
CEO
Microbiotica

Day One

Wednesday, 26th January 2022

8:05 am | European Microbiome Leaders Panel Discussion

Nigel Horscroft
CSO
MRM Health

Day 2 - Track A Evening

2:55 pm | MRM Health’s Preclinical Optimized Consortia Programs in Metabolic Disease and CNS Disorders

Nigel Titford
CEO
BioGaia

Track B - Evening - Day One

1:20 pm | From Probiotic Research to Drug Development Candidate

Nikhil Sharma
CEO
BiocorteX

Track B - Afternoon - Day One

10:20 am | The Undiscovered Country: Microbiome Therapeutics

Orly Levitan, PhD
Chief Scientist
Hygieneacare

Day 2 - Track B Evening

2:45 pm | A non-invasive patented method to obtain unique inner-colonic microbiome

Paul Carlson
Principal Investigator
FDA

Day Two

Thursday, 27th January 2022

5:25 pm | Regulatory Considerations for Microbiome Based Therapeutics

Richard Ellis
Business Development Director
Biose Industrie

Day 2 - Track B Afternoon

12:45 pm | Choosing the right CDMO for your LBP Project

Rikke C Nielson
CEO and Founder
Beo Therapeutics

Track A - Afternoon - Day One

11:50 am | Mode-Of-Action Directed Design of Microbial Therapies

Ryan Wilson
Head of Live Bio Programme
Quay Pharma

Sam Possemiers
CEO
MRM Health

Track A - Afternoon - Day One

11:20 am | MH002, the first Optimized Consortia Therapeutic in Clinical Development for Ulcerative Colitis, Manufactured as Single Drug Substance

Sandrine Claus
Chief Scientific Officer
YSOPIA Bio

Track A - Evening - Day One

1:50 pm | Christenssenella Minuta a Novel Live Biotherapy for Obesity and Metabolic Diseases

Sandrine Miller-Montgomery
President and CEO
Micronoma

Day One

Wednesday, 26th January 2022

5:30 pm | Rescuing Drugs From Failed Clinical Trials – Could the Microbiome Be of Use?

Shahram Lavasani
Founder & CEO
ImmuneBiotech AB

Day 2 - Track A Afternoon

11:15 am | Effectively Scaling Up Microbial Therapeutic Manufacturing

Shiri Meshner
VP R&D
Biomica LtD

Day One

Wednesday, 26th January 2022

8:50 am | From Functional Microbiome LBP Discovery to Clinical Proof of Concept

Sonia Timberlake
Senior Vice President
Finch

Track B - Evening - Day One

1:50 pm | A Human-First Discovery Approach: Leveraging Clinical Data to Identify Microbial Communities Driving Positive Clinical Outcomes

SPEAKER TBC

Luina Bio

Speaker TBC

Biose Industrie

Speaker TBC

Merck

Stéphane Deniau
Chief Business Officer
Biofortis

Track B - Afternoon - Day One

10:50 am | Microbiome in Clinical Trials: Booster Shot on Traps

Thomas Carton PhD
Scientific Operations Manager
Biofortis

Todd Kruegar
President and CEO
AOBiome

Day 2 - Track B Evening

2:15 pm | Drug Development in the Skin Microbiome for the Treatment of Pruritus Associated with Atopic Dermatitis

Tomas de Wouters
Co-founder and CEO
PharmaBiome

Day 2 - Track A Afternoon

11:45 am | Co-Cultivation is a Powerful Approach to Produce a Robust Functionally Designed Synthetic Consortium as a Live Biotherapeutic Product (LBP)

Tue Hodal
Chief Manufacturing Officer
Bacthera

Day 2 - Track A Afternoon

11:15 am | Effectively Scaling Up Microbial Therapeutic Manufacturing

Yakov Ginzburg
R&D Manager
Microbiome Metabolomics Technologies, Merck

Yasha (Yakov) Ginzburg was born in the former USSR and immigrated to Israel in 1990. He finished his undergraduate chemistry studies in Ben Gurion university of the Negev in Be’er Sheva where he also received his Ph.D. degree in organic chemistry in 2016, on “Development of novel catalysts for olefin metathesis reaction” under the supervision of Prof. Gabriel Lemcoff. He then joined Recipharm AB, one of the five largest pharmaceutical contract development and manufacturing organizations in the world, first as a research chemist and then as a project manager. After 4.5 years Yasha left Recipharm AB and joined Merck Sigma-Aldrich Israel where he is currently an R&D manager Microbiome Metabolomics Technologies department. In addition to working in organic, organometallic and polymer chemistry, Yasha is a Capoeira practitioner in the past 16 years and a new Yoga student.

Track A - Afternoon - Day One

10:50 am | Incorporation of Metabolomics in a Multi-Omics Microbiome analysis– A tool for clinical research

Yogesh Mudaliar
Scientist Drug Product Development
Takeda

Day 2 - Track A Evening

2:15 pm | Do’s and Don’ts’s of LBP Lyophilization

Yvonne Nyavor
Principal Scientist
Boston Analytical

Day One

Wednesday, 26th January 2022

4:00 pm | Overcoming challenges associated with performing bioburden and other purity tests for microbiome based therapeutics